Please login to the form below

Not currently logged in
Email:
Password:

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis drug works in secondary progressive MS

Novartis drug works in secondary progressive MS

Novartis drug works in secondary progressive MS. Orally-active siponimod reduces risk of disability progression. ... The new drug candidate - called siponimod (BAF312) - reduced the risk of disability progression compared with placebo in the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics